Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Operating Expenses (2019 - 2026)

Atea Pharmaceuticals' Operating Expenses history spans 8 years, with the latest figure at $48.0 million for Q1 2026.

  • Quarterly Operating Expenses rose 22.97% to $48.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $189.9 million through Mar 2026, up 17.06% year-over-year, with the annual reading at $180.9 million for FY2025, 6.25% down from the prior year.
  • Operating Expenses came in at $48.0 million for Q1 2026, down from $54.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $69.8 million in Q1 2024 to a low of $16.3 million in Q3 2022.
  • The 5-year median for Operating Expenses is $41.3 million (2025), against an average of $42.2 million.
  • Year-over-year, Operating Expenses tumbled 70.38% in 2022 and then surged 150.51% in 2023.
  • Atea Pharmaceuticals' Operating Expenses stood at $39.9 million in 2022, then increased by 16.73% to $46.6 million in 2023, then dropped by 16.2% to $39.0 million in 2024, then soared by 40.76% to $54.9 million in 2025, then fell by 12.61% to $48.0 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Operating Expenses are $48.0 million (Q1 2026), $54.9 million (Q4 2025), and $45.6 million (Q3 2025).